ClinicalTrials.gg
CompletedNCT07633093E-WALKUpdated Aug 18, 2026

Effects of a Powered Lower-Limb Exoskeleton on Walking Performance in Older Adults

An interventional study of Powered Lower-Limb Exoskeleton in Aging, Walking and Physical Function, sponsored by Hunan Normal University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Hunan Normal University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a powered wearable lower-limb exoskeleton can improve walking performance in independently ambulatory older adults aged 65 to 75 years.

The main questions it aims to answer are:

  • Does use of a powered lower-limb exoskeleton increase comfortable walking speed over 10 meters?
  • Does use of a powered lower-limb exoskeleton increase average walking speed during a 400-meter walk?

Researchers will compare walking performance in older adults during walking with the powered exoskeleton and walking without the device to determine whether the exoskeleton improves mobility. Young-adult reference participants will also complete walking assessments to provide reference values for walking performance.

Participants will:

  • Attend a screening and familiarization visit.
  • Complete walking assessments with and without the powered exoskeleton in randomized order (older adults only).
  • Perform a 10-meter walk test, a 400-meter walk test, and other physical performance assessments.
  • Complete questionnaires about balance confidence, fear of falling, and device usability.
  • Be monitored for safety events during testing.
Read the detailed description

Age-related decline in mobility is associated with reduced independence, lower quality of life, and increased risk of disability and adverse health outcomes. Walking performance is a clinically meaningful indicator of functional status in older adults, and preservation of mobility is a major goal of healthy aging. Although exercise and rehabilitation interventions can improve mobility, their benefits typically require repeated training and sustained adherence. Technologies that provide immediate assistance during walking may offer a complementary approach to supporting mobility in older adults.

Powered wearable lower-limb exoskeletons are designed to provide external mechanical assistance during locomotion. Previous studies have shown that lower-limb exoskeletons can reduce the metabolic cost of walking and improve walking performance under laboratory conditions. However, less is known about the acute effects of commercially available exoskeleton systems on clinically relevant walking outcomes in independently ambulatory older adults.

This study will evaluate the acute effects of a commercially available powered lower-limb exoskeleton on walking performance in community-dwelling older adults. The primary outcomes are comfortable gait speed during a 10-meter walk test and average walking speed during a 400-meter walk test. Secondary outcomes include lower-extremity physical performance, physiological responses during walking, perceived exertion, balance confidence, fear of falling, device usability, participant satisfaction, and safety outcomes.

The study uses a randomized crossover design. Older adult participants will complete two experimental conditions in randomized order: walking without the exoskeleton and walking with the powered exoskeleton. Participants will attend a screening and familiarization visit followed by two trial visits separated by at least 48 hours. During the familiarization visit, participants will receive device fitting and supervised practice with the exoskeleton. At each trial visit, participants will complete standardized walking and physical performance assessments under the assigned condition.

A young-adult reference group will complete no-device walking assessments to provide reference values for walking performance. Exploratory analyses will examine whether exoskeleton-assisted walking reduces the performance gap between older adults and young adults.

The study hypothesis is that use of the powered exoskeleton will improve both short-distance and sustained walking performance in older adults and partially reduce the mobility performance gap between older and young adults.

02

Conditions studied

  • Aging
  • Walking
  • Physical Function
  • Mobility Limitation

Browse trials for

Keywords

  • Exoskeleton
  • Wearable Robotics
  • Gait Speed
  • Assistive Technology
  • Mobility Assistance
03

In context

Mobility Limitation

383 studies on the registry are indexed under Mobility Limitation; 106 are open to participants now.

This study's enrollment of 34 is below the median of 46 across 318 interventional studies indexed under Mobility Limitation.

Browse Mobility Limitation studies →

Lead sponsor

Hunan Normal University is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older adults aged 65 to 75 years who are community-dwelling, independently ambulatory, able to walk independently on level ground, able to maintain standing balance without personal assistance, and able to understand study instructions.
  • Young-adult reference participants aged 18 to 22 years who are healthy university students without known conditions affecting walking or balance.

Exclusion criteria

Exclusion Criteria:

  • Self-reported neurological disease affecting gait or balance.
  • Major musculoskeletal injury or surgery affecting walking within the previous 6 months.
  • Uncontrolled cardiopulmonary disease.
  • Severe visual or vestibular impairment affecting safe walking.
  • Current lower-limb pain that limits walking.
  • Cognitive impairment that prevents or protocol adherence.
  • Any condition judged by the study team to make participation unsafe.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Older Adults

    Community-dwelling older adults aged 65-75 years who complete walking assessments under both no-device and powered-exoskeleton conditions in randomized order using a crossover design. Participants attend a screening and familiarization visit followed by two trial visits.

    Device: Powered Lower-Limb Exoskeleton

  • No intervention
    Young Adult Reference Participants

    Healthy young adults aged 18-22 years who complete no-device walking assessments to provide reference values for walking performance. Participants are not randomized and do not receive the powered exoskeleton intervention.

Interventions

  • DevicePowered Lower-Limb Exoskeleton

    A commercially available powered wearable lower-limb exoskeleton (VIATRIX; ULS Robotics Co., Ltd., Shanghai, China) designed to provide bilateral lower-limb assistance during walking. The device is worn around the pelvis and lower limbs and provides powered assistance through bilateral actuation. During powered-device assessments, participants use the adaptive assistive walking mode following device fitting and familiarization procedures.

06

What researchers measure

Primary outcomes

  1. 10-Meter Comfortable Gait Speed

    Comfortable gait speed (m/s) measured during a 10-meter walk test. Participants walk at their usual comfortable speed along a flat indoor walkway. Two trials are completed, and the mean gait speed is used for analysis.

    Time frame: During each trial visit following completion of the assigned study condition (up to 5 days)

  2. 400-Meter Average Walking Speed

    Average walking speed (m/s) measured during a 400-meter walk test. Participants walk 400 meters at a self-selected comfortable speed on an indoor walkway. Average walking speed is calculated as total walking distance divided by total completion time.

    Time frame: During each trial visit following completion of the assigned study condition (up to 5 days)

Secondary outcomes

  1. Short Physical Performance Battery Score

    Lower-extremity physical performance assessed using the Short Physical Performance Battery. The test includes standing balance, short-distance gait speed, and repeated chair-stand performance. Component scores are summed to produce a total score ranging from 0 to 12, with higher scores indicating better physical performance.

    Time frame: During each trial visit following the assigned study condition, up to 5 days.

  2. Mean Heart Rate During the 400-Meter Walk

    Mean heart rate recorded continuously during the 400-meter walk test using a wrist-worn optical heart-rate monitor.

    Time frame: During each trial visit following the assigned study condition, up to 5 days.

  3. Borg Rating of Perceived Exertion

    Perceived exertion is assessed immediately after the 400-meter walk test using the Borg Rating of Perceived Exertion Scale. Scores range from 6 to 20, where 6 indicates "no exertion at all" and 20 indicates "maximal exertion." Higher scores indicate greater perceived exertion and a worse outcome.

    Time frame: Immediately after the 400-meter walk test during each trial visit, up to 5 days.

  4. Fear of Falling 10-Rating Scale Score

    Immediate fear of falling will be assessed after each trial condition using the single-item Fear of Falling 10-Point Rating Scale. Participants will rate how concerned they were about falling during the walking and physical performance tests completed during that visit. Scores range from 0 to 10, where 0 indicates "not concerned at all" and 10 indicates "extremely concerned." Higher scores indicate greater fear of falling and a worse outcome.

    Time frame: After physical performance testing during each trial visit, up to 5 days.

  5. Activities-specific Balance Confidence Scale Score

    Balance confidence will be assessed after each trial condition using the Activities-specific Balance Confidence Scale. The scale includes 16 activities, each rated from 0%, indicating no confidence in maintaining balance, to 100%, indicating complete confidence in maintaining balance. The total score is calculated as the mean of the 16 item scores and ranges from 0 to 100. Higher scores indicate greater balance confidence and a better outcome.

    Time frame: After physical performance testing during each trial visit, up to 5 days.

  6. System Usability Scale Score

    Perceived usability of the powered lower-limb exoskeleton will be assessed after the powered-device condition using the 10-item System Usability Scale. Item responses are converted and summed to produce a total score ranging from 0 to 100. Higher scores indicate greater perceived usability of the exoskeleton and a better outcome.

    Time frame: After completion of the powered-device trial visit, up to 5 days.

  7. Quebec User Evaluation of Satisfaction With Assistive Technology 2.0 Device Subscale Score

    Participant satisfaction with the powered lower-limb exoskeleton will be assessed after the powered-device condition using the eight-item device subscale of the Quebec User Evaluation of Satisfaction With Assistive Technology 2.0. Each item is rated from 1, indicating "not satisfied at all," to 5, indicating "very satisfied." The device-subscale score is calculated as the mean of the valid device-item ratings and ranges from 1 to 5. Higher scores indicate greater satisfaction with the exoskeleton and a better outcome.

    Time frame: After completion of the powered-device trial visit, up to 5 days.

Other outcomes

  1. Number of Falls

    Number of falls occurring during study procedures. A fall is defined as an event in which the participant comes to rest inadvertently on the ground, floor, or another lower level.

    Time frame: From enrollment through completion of the final study visit, up to 5 days.

  2. Number of Near-Loss-of-Balance Events

    Number of near-loss-of-balance events occurring during study procedures. A near-loss-of-balance event is defined as an observable unintended balance disturbance requiring a corrective response to prevent a fall.

    Time frame: From enrollment through completion of the final study visit, up to 5 days.

  3. Number of Device-Related Adverse Events

    Number of adverse events judged to be caused by, probably caused by, or associated with use of the powered lower-limb exoskeleton.

    Time frame: From enrollment through completion of the final study visit, up to 5 days.

07

Study locations

1 site
  • Hunan Normal University
    Changsha, 81000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Aug 2026, 1 month.

Of 201 non-industry interventional studies with no phase under Mobility Limitation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's 1 month is below that.

Counting every sponsor, half of 206 studies reached it within 17 months; a quarter within 7 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 8, 2026
StartActual
Jul 1, 2026
Primary completionActual
Aug 16, 2026
CompletionActual
Aug 16, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07633093
Lead sponsor
Hunan Normal University
Responsible party
Yang Zhang (Independent Scientific Advisor, Hunan Normal University) — Principal investigator
First posted
Jun 8, 2026
Start date
Jul 1, 2026
Primary completion
Aug 16, 2026
Completion
Aug 16, 2026
Last update
Aug 18, 2026

Study contacts

Yang Zhang, PhD
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion